vs
Side-by-side financial comparison of Vita Coco Company, Inc. (COCO) and Vericel Corp (VCEL). Click either name above to swap in a different company.
Vita Coco Company, Inc. is the larger business by last-quarter revenue ($179.8M vs $92.9M, roughly 1.9× Vericel Corp). Vericel Corp runs the higher net margin — 25.0% vs 17.0%, a 8.1% gap on every dollar of revenue. On growth, Vita Coco Company, Inc. posted the faster year-over-year revenue change (37.3% vs 23.3%). Over the past eight quarters, Vericel Corp's revenue compounded faster (34.6% CAGR vs 11.7%).
The Vita Coco Company, doing business simply as Vita Coco, is an American beverage company which mainly sells coconut water. The largest brand globally in coconut/plant waters, Vita Coco has operations in 31 countries as of 2016. It is a benefit corporation. The company is owned by All Market Inc.
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.
COCO vs VCEL — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $179.8M | $92.9M |
| Net Profit | $30.5M | $23.2M |
| Gross Margin | 39.9% | 78.7% |
| Operating Margin | 18.7% | 24.1% |
| Net Margin | 17.0% | 25.0% |
| Revenue YoY | 37.3% | 23.3% |
| Net Profit YoY | 61.4% | 17.3% |
| EPS (diluted) | $0.50 | $0.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $179.8M | — | ||
| Q4 25 | $127.8M | $92.9M | ||
| Q3 25 | $182.3M | $67.5M | ||
| Q2 25 | $168.8M | $63.2M | ||
| Q1 25 | $130.9M | $52.6M | ||
| Q4 24 | $127.3M | $75.4M | ||
| Q3 24 | $132.9M | $57.9M | ||
| Q2 24 | $144.1M | $52.7M |
| Q1 26 | $30.5M | — | ||
| Q4 25 | $5.5M | $23.2M | ||
| Q3 25 | $24.0M | $5.1M | ||
| Q2 25 | $22.9M | $-553.0K | ||
| Q1 25 | $18.9M | $-11.2M | ||
| Q4 24 | $3.4M | $19.8M | ||
| Q3 24 | $19.3M | $-901.0K | ||
| Q2 24 | $19.1M | $-4.7M |
| Q1 26 | 39.9% | — | ||
| Q4 25 | 34.9% | 78.7% | ||
| Q3 25 | 37.7% | 73.5% | ||
| Q2 25 | 36.3% | 73.7% | ||
| Q1 25 | 36.7% | 69.0% | ||
| Q4 24 | 32.5% | 77.6% | ||
| Q3 24 | 38.8% | 71.9% | ||
| Q2 24 | 40.8% | 69.5% |
| Q1 26 | 18.7% | — | ||
| Q4 25 | 8.0% | 24.1% | ||
| Q3 25 | 15.3% | 5.1% | ||
| Q2 25 | 14.9% | -3.2% | ||
| Q1 25 | 14.7% | -24.3% | ||
| Q4 24 | 3.4% | 24.5% | ||
| Q3 24 | 15.5% | -4.3% | ||
| Q2 24 | 20.8% | -11.5% |
| Q1 26 | 17.0% | — | ||
| Q4 25 | 4.3% | 25.0% | ||
| Q3 25 | 13.2% | 7.5% | ||
| Q2 25 | 13.6% | -0.9% | ||
| Q1 25 | 14.4% | -21.4% | ||
| Q4 24 | 2.6% | 26.3% | ||
| Q3 24 | 14.5% | -1.6% | ||
| Q2 24 | 13.2% | -8.9% |
| Q1 26 | $0.50 | — | ||
| Q4 25 | $0.10 | $0.46 | ||
| Q3 25 | $0.40 | $0.10 | ||
| Q2 25 | $0.38 | $-0.01 | ||
| Q1 25 | $0.31 | $-0.23 | ||
| Q4 24 | $0.06 | $0.40 | ||
| Q3 24 | $0.32 | $-0.02 | ||
| Q2 24 | $0.32 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $201.9M | $137.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $352.2M | $354.6M |
| Total Assets | $488.3M | $488.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $201.9M | — | ||
| Q4 25 | $196.9M | $137.5M | ||
| Q3 25 | $203.7M | $135.4M | ||
| Q2 25 | $167.0M | $116.9M | ||
| Q1 25 | $153.6M | $112.9M | ||
| Q4 24 | $164.7M | $116.2M | ||
| Q3 24 | $156.7M | $101.7M | ||
| Q2 24 | $150.1M | $102.5M |
| Q1 26 | $352.2M | — | ||
| Q4 25 | $331.5M | $354.6M | ||
| Q3 25 | $323.7M | $321.9M | ||
| Q2 25 | $296.9M | $306.8M | ||
| Q1 25 | $277.9M | $295.5M | ||
| Q4 24 | $258.8M | $292.0M | ||
| Q3 24 | $252.1M | $257.5M | ||
| Q2 24 | $232.0M | $243.0M |
| Q1 26 | $488.3M | — | ||
| Q4 25 | $461.2M | $488.0M | ||
| Q3 25 | $461.3M | $453.3M | ||
| Q2 25 | $421.1M | $435.6M | ||
| Q1 25 | $384.0M | $424.6M | ||
| Q4 24 | $362.4M | $432.7M | ||
| Q3 24 | $353.1M | $390.4M | ||
| Q2 24 | $323.0M | $376.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $15.0M |
| Free Cash FlowOCF − Capex | — | $12.8M |
| FCF MarginFCF / Revenue | — | 13.8% |
| Capex IntensityCapex / Revenue | — | 2.4% |
| Cash ConversionOCF / Net Profit | — | 0.65× |
| TTM Free Cash FlowTrailing 4 quarters | — | $24.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-3.9M | $15.0M | ||
| Q3 25 | $39.1M | $22.1M | ||
| Q2 25 | $21.8M | $8.2M | ||
| Q1 25 | $-9.8M | $6.6M | ||
| Q4 24 | $6.9M | $22.2M | ||
| Q3 24 | $9.3M | $10.2M | ||
| Q2 24 | $26.9M | $18.5M |
| Q1 26 | — | — | ||
| Q4 25 | $-7.1M | $12.8M | ||
| Q3 25 | $35.6M | $19.5M | ||
| Q2 25 | $20.9M | $81.0K | ||
| Q1 25 | $-10.4M | $-7.6M | ||
| Q4 24 | $6.8M | $8.5M | ||
| Q3 24 | $8.9M | $-9.2M | ||
| Q2 24 | $26.6M | $1.8M |
| Q1 26 | — | — | ||
| Q4 25 | -5.6% | 13.8% | ||
| Q3 25 | 19.6% | 28.8% | ||
| Q2 25 | 12.4% | 0.1% | ||
| Q1 25 | -7.9% | -14.5% | ||
| Q4 24 | 5.3% | 11.2% | ||
| Q3 24 | 6.7% | -15.9% | ||
| Q2 24 | 18.5% | 3.4% |
| Q1 26 | — | — | ||
| Q4 25 | 2.5% | 2.4% | ||
| Q3 25 | 1.9% | 3.9% | ||
| Q2 25 | 0.6% | 12.9% | ||
| Q1 25 | 0.4% | 27.0% | ||
| Q4 24 | 0.1% | 18.3% | ||
| Q3 24 | 0.3% | 33.5% | ||
| Q2 24 | 0.2% | 31.8% |
| Q1 26 | — | — | ||
| Q4 25 | -0.70× | 0.65× | ||
| Q3 25 | 1.63× | 4.35× | ||
| Q2 25 | 0.95× | — | ||
| Q1 25 | -0.52× | — | ||
| Q4 24 | 2.05× | 1.12× | ||
| Q3 24 | 0.48× | — | ||
| Q2 24 | 1.41× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
COCO
| Subtotal | $148.2M | 82% |
| Private Label | $24.4M | 14% |
| Other | $7.2M | 4% |
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
